Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study

David E. Griffith(National Jewish Health), Kevin Winthrop(Oregon Health & Science University), Patrick A. Flume(Medical University of South Carolina), Theodore K. Marras(University of Toronto), Kozo Morimoto(Japan Anti Tuberculosis Association), Jakko van Ingen(Radboud University Nijmegen), Doreen Addrizzo‐Harris(Unknown), Rachel Thomson(The University of Queensland), Julie V. Philley(The University of Texas Health Science Center at Tyler), Gina Eagle(Insmed (United States)), Stephen K. Field(University of Calgary), Timothy R. Aksamit(Mayo Clinic), James Nezamis(Insmed (United States)), Naoki Hasegawa(Keio University), Michael R. Loebinger(Royal Brompton & Harefield NHS Foundation Trust), Stephen J. Ruoss(National Heart Lung and Blood Institute), Felix C. Ringshausen(Medizinische Hochschule Hannover), Jae‐Joon Yim(Seoul National University Hospital), Luigi Ruffo Codecasa(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Richard J. Wallace(The University of Texas at Tyler), Anne E. O’Donnell(Georgetown University), Adam T. Hill(Centre for Inflammation Research), Chris Coulter(Queensland Health), Lucy Morgan(The University of Sydney)

American Journal of Respiratory and Critical Care Medicine

September 14, 2018

Cited by 343

|Arthritis Care & Research|2012|1.8k

|New England Journal of Medicine|2015|1.6k

|CHEST Journal|2006|1.2k

|CHEST Journal|2013|901

|European Respiratory Journal|2020|876

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized Study